Navigating the regulatory landscape for synthetic growth hormone-releasing hormone (GHRH) analogs requires precise understanding of institutional guidelines and chemical classifications. This reference guide examines the legal status, analytical verification standards, and biochemical mechanics of CJC-1295 DAC for non-clinical laboratory research.
Navigating the regulatory landscape for synthetic growth hormone-releasing hormone (GHRH) analogs requires precise understanding of institutional guidelines and chemical classifications. This reference guide examines the legal status, analytical verification standards, and biochemical mechanics of CJC-1295 DAC for non-clinical laboratory research.
In the United States and most international jurisdictions, purchasing and possessing CJC-1295 DAC legal status is maintained strictly when the compound is designated as a reference standard or research chemical intended for non-clinical in vitro and animal model experimentation. Because it is not an FDA-approved human drug or a scheduled substance under the Controlled Substances Act (CSA), institutions may acquire high-purity CJC-1295 DAC provided it is explicitly labeled 'For Laboratory Research Use Only' and never introduced into clinical settings.
Regulatory agencies differentiate between unapproved pharmaceutical formulations intended for human therapy and legitimate chemical reagents used by academic, commercial, and medical laboratories. Compliance hinges entirely on the intent of use, proper labeling, institutional control, and sourcing through verified domestic channels that adhere to strict laboratory standards.
Synthetic growth hormone-releasing hormone (GHRH) peptides occupy a specific regulatory framework. Unlike anabolic steroids or narcotic compounds, CJC-1295 with Drug Affinity Complex (DAC) is not listed on the Drug Enforcement Administration (DEA) schedules. Consequently, possession of the material by research institutions does not require federal controlled-substance registration.
However, because the compound possesses biological activity targeting the pituitary axis in preclinical models, regulatory bodies such as the U.S. Food and Drug Administration (FDA) regulate its commercial positioning. Distributing CJC-1295 DAC with claims of therapeutic benefits, human administration guidelines, or dietary supplement status constitutes a violation of federal law. Researchers and facility procurement officers sourcing through wholesale lab accounts must ensure that all materials are handled in accordance with institutional biosafety protocols and non-clinical research mandates.
CJC-1295 DAC is a modified 30-amino-acid peptide analog of GHRH (specifically modified GRF 1-29) incorporating a bi-functional maleimidopropionic acid (DAC) linker at the C-terminus. This structural addition fundamentally alters the pharmacokinetics of the peptide when evaluated in preclinical research models.
In animal studies, the maleimide group reacts covalently with reactive lysine residues on circulating serum albumin upon administration. This albumin-binding mechanism protects the peptide from rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidase (NEP). Consequently, while natural GHRH and short-acting analogs possess elimination half-lives measured in minutes, CJC-1295 DAC exhibits an extended half-life of approximately 6 to 8 days in experimental models, permitting sustained stimulation of growth hormone receptors.
When evaluating candidates for neuroendocrine and metabolic research, investigators frequently compare CJC-1295 DAC against related synthetic secretagogues. Understanding these structural and functional differences is vital for selecting the appropriate compound for experimental design.
A primary comparison involves CJC-1295 No DAC (modified GRF 1-29), which lacks the albumin-binding linker and therefore exhibits a brief half-life (~30 minutes) that yields rapid, transient growth hormone spikes. In contrast, CJC-1295 DAC produces baseline elevation of GH and downstream IGF-1 over extended durations. When compared to classical analogs like Sermorelin, which represents the truncated 1-29 sequence of native GHRH, CJC-1295 DAC demonstrates vastly superior enzymatic stability. Additionally, researchers often evaluate GHRH analogs in combination with growth hormone secretagogue receptor (GHSR-1a) agonists such as Ipamorelin to study synergistic pituitary stimulation within broader growth hormone secretagogues research protocols.
Preclinical investigations demonstrate that CJC-1295 DAC binds selectively to the GHRH receptor on pituitary somatotropes. Activation of this G-protein coupled receptor stimulates adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) signaling cascades. This pathway prompts the synthesis and secretion of endogenous growth hormone.
In vivo rodent models indicate that sustained GH release driven by CJC-1295 DAC promotes hepatic transcription and systemic elevation of Insulin-like Growth Factor 1 (IGF-1). In laboratory models of tissue injury, elevated IGF-1 concentrations correlate with accelerated collagen synthesis, enhanced nitrogen retention, and improved connective tissue matrix remodeling. Researchers interested in broader cellular pathways can access technical literature via our research library hub.
To satisfy institutional auditing standards and ensure experimental reproducibility, researchers must source research peptides that meet rigorous analytical criteria. PX1 Research enforces stringent quality assurance standards across every production lot:
- **USA Manufacturing:** Synthesized in compliance with strict domestic quality management systems. - **High Purity (RP-HPLC):** Verified to exceed ≥98% purity using Reverse-Phase High-Performance Liquid Chromatography. - **Identity Verification (MS):** Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise molecular weight matching the CJC-1295 DAC sequence. - **Endotoxin Testing:** Quantitative Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin levels below 0.5 EU/mg, preventing confounding inflammatory responses in cell cultures or animal models. - **ISO 17025 Accreditation:** Analytical verification conducted by independent, third-party analytical laboratories. - **Lot-Specific COA:** Comprehensive Certificate of Analysis attached to every lot for complete traceability. - **Domestic Fulfillment:** Dispatched directly from state-of-the-art facilities in California and Arizona with same-day shipping (Monday–Friday).
Proper handling of lyophilized peptides is critical to maintain structural integrity and prevent aggregation or enzymatic degradation prior to bioassays. Standard laboratory reconstitution protocols for CJC-1295 DAC involve working under a laminar flow hood using sterile technique.
Lyophilized CJC-1295 DAC should be reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline depending on the assay requirements. The diluent should be directed down the internal glass wall of the vial rather than sprayed directly onto the peptide cake, followed by gentle swirl agitation—never vortexing. Reconstituted solutions maintain stability at 2°C to 8°C for short-term evaluation, while aliquoted stock solutions should be stored at -20°C or -80°C to avoid repeated freeze-thaw cycles. Explore our catalog of all research peptides for complete technical documentation.
Ensuring full compliance when procuring CJC-1295 DAC requires adherence to institutional risk management practices. Receiving facilities should verify that all incoming shipments are accompanied by a complete Safety Data Sheet (SDS) and clear regulatory labeling specifying 'For Research Use Only — Not for Human or Veterinary Administration.'
Proper chain-of-custody documentation requires maintaining lot-matched COAs alongside chemical inventory logs. By establishing unambiguous segregation between investigational reagents and clinical supplies, academic and commercial laboratories insulate themselves from regulatory exposure while advancing legitimate scientific inquiry into GHRH analogs overview.
Is cjc-1295 dac legal to purchase for research in the United States?
Yes. CJC-1295 DAC is fully legal to purchase and possess in the United States when acquired by research laboratories and qualified investigators for non-clinical research use only. It is not a scheduled controlled substance under federal law.
Is CJC-1295 DAC classified as a controlled substance by the DEA?
No. CJC-1295 DAC is not listed on any schedule under the Controlled Substances Act (CSA) regulated by the DEA.
What distinguishes CJC-1295 DAC from CJC-1295 No DAC in research applications?
CJC-1295 DAC contains a Drug Affinity Complex linker that binds to circulating albumin in animal models, extending its biological half-life to approximately 6-8 days. CJC-1295 No DAC lacks this linker and features a half-life of roughly 30 minutes.
What purity standard should CJC-1295 DAC meet for valid experimental use?
Laboratory-grade CJC-1295 DAC should exhibit a purity level of ≥98% as verified by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry.
How is CJC-1295 DAC shipped to preserve stability?
PX1 Research ships lyophilized CJC-1295 DAC in temperature-controlled packaging from domestic centers in CA and AZ, offering same-day dispatch for orders placed Monday through Friday.
What laboratory diluent is recommended for reconstituting CJC-1295 DAC?
Lyophilized CJC-1295 DAC is typically reconstituted using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) to maintain solution sterility during multi-use experimental protocols.
Why is endotoxin testing critical for CJC-1295 DAC research batches?
Endotoxin levels above acceptable thresholds (<0.5 EU/mg) can trigger non-specific inflammatory signaling in cell cultures or animal models, compromising experimental validity.
Can CJC-1295 DAC be co-studied with ghrelin mimetics in laboratory models?
Yes. In preclinical research, CJC-1295 DAC is frequently evaluated in tandem with selective GHSR-1a agonists like Ipamorelin to investigate dual-receptor secretagogue synergy.
Where can laboratories access third-party COAs for CJC-1295 DAC?
PX1 Research provides lot-specific Certificates of Analysis (COA) directly on product pages and alongside every shipped order, featuring RP-HPLC and mass spectrometry data from ISO 17025 accredited labs.
What regulatory statement must appear on CJC-1295 DAC research packaging?
Packaging must clearly state 'For Laboratory Research Use Only; Not for Human, Clinical, or Veterinary Use' to comply with federal regulations governing non-approved chemical compounds.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.